The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TSHA | +150.76% | -75.32% | -24.4% | -79% |
| S&P | +16.23% | +94.45% | +14.22% | +108% |
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.99M | 78.6% |
| Gross Profit | $1.71M | 110.5% |
| Gross Margin | 86.05% | 13.0% |
| Market Cap | $604.13M | 44.2% |
| Market Cap / Employee | $8.28M | 0.0% |
| Employees | 73 | 40.4% |
| Net Income | -$26.88M | -28.4% |
| EBITDA | -$26.48M | -26.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $313.21M | 80.8% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $58.03M | 3.7% |
| Short Term Debt | $2.15M | 22.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -34.74% | 46.4% |
| Return On Invested Capital | -112.75% | -178.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.18M | 7.0% |
| Operating Free Cash Flow | -$20.18M | 6.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.72 | 3.99 | 3.98 | 8.60 | 10.58% |
| Price to Sales | 54.29 | 42.55 | 51.82 | 85.00 | 109.82% |
| Price to Tangible Book Value | 3.72 | 3.99 | 3.98 | 8.60 | 10.59% |
| Enterprise Value to EBITDA | -21.33 | -14.22 | -15.11 | -16.44 | -14.97% |
| Return on Equity | -114.8% | -121.9% | -159.3% | -51.9% | -83.73% |
| Total Debt | $62.54M | $63.95M | $62.03M | $60.18M | 4.25% |
TSHA earnings call for the period ending June 30, 2022.
TSHA earnings call for the period ending March 31, 2022.
TSHA earnings call for the period ending December 31, 2021.
TSHA earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
